Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC cut its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 2.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 150,854 shares of the biotechnology company’s stock after selling 3,312 shares during the quarter. Mutual of America Capital Management LLC owned 0.05% of Exelixis worth $5,023,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC boosted its holdings in shares of Exelixis by 124.0% in the 3rd quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock valued at $46,473,000 after buying an additional 991,494 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in Exelixis by 82.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company’s stock valued at $52,884,000 after acquiring an additional 704,786 shares during the period. Caisse DE Depot ET Placement DU Quebec acquired a new position in Exelixis in the third quarter valued at approximately $14,979,000. Burney Co. bought a new position in shares of Exelixis during the fourth quarter valued at approximately $12,267,000. Finally, Robeco Institutional Asset Management B.V. raised its position in shares of Exelixis by 263.1% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 483,064 shares of the biotechnology company’s stock worth $12,536,000 after purchasing an additional 350,026 shares during the period. Institutional investors and hedge funds own 85.27% of the company’s stock.

Insiders Place Their Bets

In related news, Director Jack L. Wyszomierski sold 8,768 shares of the stock in a transaction on Friday, February 28th. The stock was sold at an average price of $37.80, for a total value of $331,430.40. Following the completion of the transaction, the director now owns 356,605 shares in the company, valued at $13,479,669. This trade represents a 2.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Mary C. Beckerle sold 12,210 shares of Exelixis stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $34.88, for a total value of $425,884.80. Following the completion of the transaction, the director now directly owns 30,406 shares in the company, valued at $1,060,561.28. This represents a 28.65 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 130,343 shares of company stock worth $4,789,234. 2.85% of the stock is owned by insiders.

Exelixis Stock Down 0.7 %

Shares of EXEL stock opened at $38.29 on Wednesday. The stock has a 50-day simple moving average of $34.72 and a 200 day simple moving average of $31.87. The stock has a market capitalization of $10.72 billion, a P/E ratio of 21.63, a P/E/G ratio of 1.13 and a beta of 0.53. Exelixis, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $39.30.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. On average, sell-side analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on EXEL shares. JMP Securities restated a “market outperform” rating and set a $41.00 price objective on shares of Exelixis in a research report on Thursday, January 23rd. Bank of America lowered shares of Exelixis from a “buy” rating to a “neutral” rating and upped their price target for the stock from $35.00 to $39.00 in a research report on Tuesday, December 17th. Piper Sandler increased their price objective on shares of Exelixis from $37.00 to $38.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Exelixis in a research note on Thursday, February 13th. Finally, StockNews.com upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 19th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $37.24.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.